Use of multiple-dose activated charcoal in phenytoin toxicity

Carol E. Howard, Carol E. Howard, Carol E. Howard, R. Shane Roberts, Daniel Ely, Robert A. Moye, Robert A. Moye

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of phenytoin toxicity successfully treated with multiple-dose activated charcoal. CASE SUMMARY: A 36-year-old man was first admitted with chronic phenytoin toxicity secondary to hepatitis and was treated symptomatically. His serum phenytoin concentration was 149.8 μmol/L on admission and decreased slowly over his 6-day hospitalization to 134.8 μmol/L. Upon readmission approximately 24 hours later, his phenytoin concentration was 186.7 μmol/L. Because of acute phenytoin toxicity, he was treated with multiple-dose activated charcoal. His phenytoin concentration after four doses of activated charcoal returned to the therapeutic range within 36 hours and his symptoms abated quickly, thus decreasing his hospital stay. DISCUSSION: The exact mechanism of action of multiple-dose activated charcoal to decrease serum phenytoin concentrations is unknown. Several mechanisms of action have been reported in the literature and are discussed. CONCLUSIONS: Multiple-dose activated charcoal was used successfully in treating acute phenytoin toxicity in our patient. Based on his previous admission for chronic phenytoin toxicity, his hospital stay was reduced by three days. The use of multiple-dose activated charcoal in acute phenytoin toxicity has potential therapeutic and financial implications.

Original languageEnglish (US)
Pages (from-to)201-203
Number of pages3
JournalAnnals of Pharmacotherapy
Volume28
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Charcoal
Phenytoin
His-His-His-His-His-His
Length of Stay
Serum
Hepatitis
Hospitalization

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Howard, C. E., Howard, C. E., Howard, C. E., Roberts, R. S., Ely, D., Moye, R. A., & Moye, R. A. (1994). Use of multiple-dose activated charcoal in phenytoin toxicity. Annals of Pharmacotherapy, 28(2), 201-203. https://doi.org/10.1177/106002809402800210

Use of multiple-dose activated charcoal in phenytoin toxicity. / Howard, Carol E.; Howard, Carol E.; Howard, Carol E.; Roberts, R. Shane; Ely, Daniel; Moye, Robert A.; Moye, Robert A.

In: Annals of Pharmacotherapy, Vol. 28, No. 2, 01.01.1994, p. 201-203.

Research output: Contribution to journalArticle

Howard, CE, Howard, CE, Howard, CE, Roberts, RS, Ely, D, Moye, RA & Moye, RA 1994, 'Use of multiple-dose activated charcoal in phenytoin toxicity', Annals of Pharmacotherapy, vol. 28, no. 2, pp. 201-203. https://doi.org/10.1177/106002809402800210
Howard CE, Howard CE, Howard CE, Roberts RS, Ely D, Moye RA et al. Use of multiple-dose activated charcoal in phenytoin toxicity. Annals of Pharmacotherapy. 1994 Jan 1;28(2):201-203. https://doi.org/10.1177/106002809402800210
Howard, Carol E. ; Howard, Carol E. ; Howard, Carol E. ; Roberts, R. Shane ; Ely, Daniel ; Moye, Robert A. ; Moye, Robert A. / Use of multiple-dose activated charcoal in phenytoin toxicity. In: Annals of Pharmacotherapy. 1994 ; Vol. 28, No. 2. pp. 201-203.
@article{90adef3cfdf64b8083f020d391885e20,
title = "Use of multiple-dose activated charcoal in phenytoin toxicity",
abstract = "OBJECTIVE: To report a case of phenytoin toxicity successfully treated with multiple-dose activated charcoal. CASE SUMMARY: A 36-year-old man was first admitted with chronic phenytoin toxicity secondary to hepatitis and was treated symptomatically. His serum phenytoin concentration was 149.8 μmol/L on admission and decreased slowly over his 6-day hospitalization to 134.8 μmol/L. Upon readmission approximately 24 hours later, his phenytoin concentration was 186.7 μmol/L. Because of acute phenytoin toxicity, he was treated with multiple-dose activated charcoal. His phenytoin concentration after four doses of activated charcoal returned to the therapeutic range within 36 hours and his symptoms abated quickly, thus decreasing his hospital stay. DISCUSSION: The exact mechanism of action of multiple-dose activated charcoal to decrease serum phenytoin concentrations is unknown. Several mechanisms of action have been reported in the literature and are discussed. CONCLUSIONS: Multiple-dose activated charcoal was used successfully in treating acute phenytoin toxicity in our patient. Based on his previous admission for chronic phenytoin toxicity, his hospital stay was reduced by three days. The use of multiple-dose activated charcoal in acute phenytoin toxicity has potential therapeutic and financial implications.",
author = "Howard, {Carol E.} and Howard, {Carol E.} and Howard, {Carol E.} and Roberts, {R. Shane} and Daniel Ely and Moye, {Robert A.} and Moye, {Robert A.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1177/106002809402800210",
language = "English (US)",
volume = "28",
pages = "201--203",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "2",

}

TY - JOUR

T1 - Use of multiple-dose activated charcoal in phenytoin toxicity

AU - Howard, Carol E.

AU - Howard, Carol E.

AU - Howard, Carol E.

AU - Roberts, R. Shane

AU - Ely, Daniel

AU - Moye, Robert A.

AU - Moye, Robert A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - OBJECTIVE: To report a case of phenytoin toxicity successfully treated with multiple-dose activated charcoal. CASE SUMMARY: A 36-year-old man was first admitted with chronic phenytoin toxicity secondary to hepatitis and was treated symptomatically. His serum phenytoin concentration was 149.8 μmol/L on admission and decreased slowly over his 6-day hospitalization to 134.8 μmol/L. Upon readmission approximately 24 hours later, his phenytoin concentration was 186.7 μmol/L. Because of acute phenytoin toxicity, he was treated with multiple-dose activated charcoal. His phenytoin concentration after four doses of activated charcoal returned to the therapeutic range within 36 hours and his symptoms abated quickly, thus decreasing his hospital stay. DISCUSSION: The exact mechanism of action of multiple-dose activated charcoal to decrease serum phenytoin concentrations is unknown. Several mechanisms of action have been reported in the literature and are discussed. CONCLUSIONS: Multiple-dose activated charcoal was used successfully in treating acute phenytoin toxicity in our patient. Based on his previous admission for chronic phenytoin toxicity, his hospital stay was reduced by three days. The use of multiple-dose activated charcoal in acute phenytoin toxicity has potential therapeutic and financial implications.

AB - OBJECTIVE: To report a case of phenytoin toxicity successfully treated with multiple-dose activated charcoal. CASE SUMMARY: A 36-year-old man was first admitted with chronic phenytoin toxicity secondary to hepatitis and was treated symptomatically. His serum phenytoin concentration was 149.8 μmol/L on admission and decreased slowly over his 6-day hospitalization to 134.8 μmol/L. Upon readmission approximately 24 hours later, his phenytoin concentration was 186.7 μmol/L. Because of acute phenytoin toxicity, he was treated with multiple-dose activated charcoal. His phenytoin concentration after four doses of activated charcoal returned to the therapeutic range within 36 hours and his symptoms abated quickly, thus decreasing his hospital stay. DISCUSSION: The exact mechanism of action of multiple-dose activated charcoal to decrease serum phenytoin concentrations is unknown. Several mechanisms of action have been reported in the literature and are discussed. CONCLUSIONS: Multiple-dose activated charcoal was used successfully in treating acute phenytoin toxicity in our patient. Based on his previous admission for chronic phenytoin toxicity, his hospital stay was reduced by three days. The use of multiple-dose activated charcoal in acute phenytoin toxicity has potential therapeutic and financial implications.

UR - http://www.scopus.com/inward/record.url?scp=0028345223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028345223&partnerID=8YFLogxK

U2 - 10.1177/106002809402800210

DO - 10.1177/106002809402800210

M3 - Article

VL - 28

SP - 201

EP - 203

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 2

ER -